Table 3.
Liver function and hepatic tissue blood flow in each fibrosis stage in NAFLD.
| Fibrosis Stage | NAFL | Stage 1 | Stage 2 | Stage 3 | Initial LC | Advanced LC | p-Value * | r |
|---|---|---|---|---|---|---|---|---|
| n = 15 | n = 47 | n = 30 | n = 15 | n = 25 | n = 7 | |||
| Alb (g/dL) | 4.5 ± 0.3 | 4.5 ± 0.3 | 4.4 ± 0.3 | 4.4 ± 0.3 | 4.0 ± 0.3 | 3.1 ± 0.4 | <0.001 | −0.47 |
| ChE (IU/L) | 390.1 ± 107.2 | 372.8 ± 104.3 | 346.3 ± 96.0 | 260.5 ± 149.3 | 254.8 ± 63.2 | 155.4 ± 95.7 | <0.001 | −0.52 |
| TC (mg/dL) | 200.8 ± 40.9 | 200.4 ± 33.5 | 180.3 ± 62.0 | 170.3 ± 73.9 | 179.5 ± 36.3 | 119.7 ± 39.0 | <0.01 | −0.26 |
| PT (%) | 100.8 ± 5.4 | 98.9 ± 9.0 | 96.4 ± 6.5 | 87.0 ± 10.1 | 76.4 ± 16.2 | 57.0 ± 7.7 | <0.001 | −0.69 |
| ICG-R15 (%) | 5.9 ± 2.9 | 9.8 ± 13.0 | 11.6 ± 6.6 | 17.7 ± 18.1 | 21.9 ± 12.5 | 26.0 ± 8.4 | <0.001 | 0.58 |
| HA (ng/mL) | 20.4 ± 16.5 | 53.4 ± 98.0 | 63.4 ± 51.3 | 151.4 ± 98.7 | 268.9 ± 193.9 | 347.3 ± 181.9 | <0.001 | 0.78 |
| WFA+-M2BP (C.O.I) | 0.7 ± 0.3 | 0.8 ± 0.4 | 1.2 ± 0.7 | 1.3 ± 0.6 | 1.8 ± 1.5 | 4.4 ± 0.2 | <0.001 | 0.50 |
| Plt (×104/μL) | 24.2 ± 4.5 | 23.7 ± 6.5 | 20.1 ± 5.2 | 18.3 ± 7.3 | 11.5 ± 3.5 | 5.3 ± 3.0 | <0.001 | −0.66 |
| PVTBF (mL/100 mL/min) | 41.0 ± 6.3 | 34.3 ± 7.2 | 33.8 ± 7.0 | 29.9 ± 6.7 | 29.3 ± 7.9 | 29.9 ± 2.4 | <0.001 | −0.32 |
| HATBF (mL/100 mL/min) | 23.8 ± 9.0 | 21.30 ± 10.2 | 19.6 ± 10.1 | 20.5 ± 8.3 | 18.8 ± 8.6 | 24.2 ± 6.2 | NS | −0.09 |
| THTBF (mL/100 mL/min) | 64.9 ± 13.4 | 55.6 ± 14.0 | 53.4 ± 14.2 | 48.1 ± 10.1 | 46.5 ± 10.9 | 54.9 ± 9.4 | <0.01 | −0.22 |
| P/A ratio Fibro | 1.9 ± 0.7 | 1.9 ± 0.7 | 2.0 ± 0.6 | 1.6 ± 0.5 | 1.6 ± 0.5 | 1.4 ± 0.4 | NS | −0.15 |
* Spearman’s rank correlation coefficient was used to examine correlations of TBF with the progression of fibrosis; NS: not significant; P/A ratio: portal flow/hepatic arterial flow ratio.